View Financial HealthCV Sciences 배당 및 자사주 매입배당 기준 점검 0/6CV Sciences 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공지 • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.공지 • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026공지 • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025공지 • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025공지 • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025공지 • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.공지 • Feb 20CV Sciences, Inc. announced that it has received $1.2 million in fundingCV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000공지 • Nov 22CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million.CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions.공지 • Nov 08CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024공지 • Aug 27CV Sciences, Inc. Launches +PlusHLTHCV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies.공지 • Aug 07CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024공지 • Jun 08CV Sciences, Inc. Elects Bill Mccorkle as DirectorsCV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors.공지 • May 10CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024공지 • Apr 13CV Sciences, Inc., Annual General Meeting, Jun 03, 2024CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors.공지 • Mar 26CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives.공지 • Mar 22CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024공지 • Dec 14CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million.CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023.공지 • Nov 10CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023공지 • Sep 06CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health.공지 • Aug 03CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023공지 • May 10CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023공지 • Jan 19CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.공지 • Jan 06CV Sciences, Inc. Announces Launch of ProCBD™ Product LineCV Sciences, Inc. announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners. Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review. Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.공지 • Nov 06CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product LineCV Sciences, Inc. announced the launch of PlusCBD™ Pet, a full line of hemp extracts formulated exclusively for dogs and cats. Made with the same trusted hemp extracts used in CV Sciences’ CBD products, PlusCBD™ Pet is available in 250mg and 500mg formats with pet friendly flavors, including beef, chicken, peanut butter and salmon, as well as unflavored. PlusCBD™ Pet will be sold across the Company’s natural and online retail channels, with plans to expand into the pet specialty channel and food, drug and mass retail channel.공지 • Oct 07CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product LaunchesCV Sciences, Inc. announced a comprehensive refresh of its PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products over the next 45 days. The new PlusCBD™ brand is a refinement and modernization that includes new packaging with a contemporary color palette and a post-modern aesthetic to relay each product’s value proposition across the product offering. The 30+ new product launch includes eight new, innovative products featuring extra strength gummies and maximum strength softgels. The refreshed PlusCBD™ packaging features its new, prominently displayed CV Sciences logo, transparent QR code labeling linked to lab reports to assure customers of the unrivaled quality, and the milligrams of CBD per serving on the label.공지 • Jul 24CV Sciences, Inc. to Report Q2, 2020 Results on Aug 06, 2020CV Sciences, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CVSI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CVSI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장CV Sciences 배당 수익률 vs 시장CVSI의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CVSI)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Personal Products)3.2%분석가 예측 (CVSI) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CVSI 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CVSI 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CVSI 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CVSI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/07 21:48종가2026/05/07 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CV Sciences, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Pablo ZuanicCantor Fitzgerald & Co.Michael GrondahlNorthland Capital MarketsMichael LaveryPiper Sandler Companies2명의 분석가 더 보기
공지 • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2026CV Sciences, Inc., Annual General Meeting, Jun 02, 2026.
공지 • Mar 25CV Sciences, Inc. to Report Q4, 2025 Results on Mar 26, 2026CV Sciences, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
공지 • Nov 11CV Sciences, Inc. to Report Q3, 2025 Results on Nov 13, 2025CV Sciences, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
공지 • Aug 09CV Sciences, Inc. to Report Q2, 2025 Results on Aug 13, 2025CV Sciences, Inc. announced that they will report Q2, 2025 results After-Market on Aug 13, 2025
공지 • May 10CV Sciences, Inc. to Report Q1, 2025 Results on May 14, 2025CV Sciences, Inc. announced that they will report Q1, 2025 results After-Market on May 14, 2025
공지 • Apr 17CV Sciences, Inc., Annual General Meeting, Jun 02, 2025CV Sciences, Inc., Annual General Meeting, Jun 02, 2025.
공지 • Feb 20CV Sciences, Inc. announced that it has received $1.2 million in fundingCV Sciences, Inc announced that it has issued a secured promissory note in the principal amount of $1,600,000 on February 20, 2025. The Note carries an original issuance discount of $400,000
공지 • Nov 22CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million.CV Sciences, Inc. (OTCPK:CVSI) agreed to acquire Extract Labs, Inc. from Higher Love Wellness Company LLC and Craig Henderson for $2 million on November 15, 2024. The acquisition of Extract Labs involves an initial payment at closing, which includes a cash payment of $0.4 million, subject to certain holdbacks and adjustments, and the issuance of CV Sciences' common stock valued at $1 million, based on the 60-day volume weighted average price. Additionally, the sellers of Extract Labs may receive up to $0.6 million in extra shares of CV Sciences' common stock if specific revenue targets are met during the two 12-month periods following the closing date. The Acquisition is anticipated to close during the first quarter of 2025 and is subject to customary conditions.
공지 • Nov 08CV Sciences, Inc. to Report Q3, 2024 Results on Nov 14, 2024CV Sciences, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 14, 2024
공지 • Aug 27CV Sciences, Inc. Launches +PlusHLTHCV Sciences, Inc. announced the launch of +PlusHLTH, an all-new line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance, and increased vitality. Rooted in rigorous science and fortified by clinically proven wellness ingredients, the new line is now available nationwide at select retailers and from the Company's website. +PlusHLTH™ offers supplements that naturally enhance focus, mood, energy levels, metabolism, and more. Free of cannabinoids, +PlusHLTH™'s collection of innovative supplements includes: Clarity: The ultimate cognitive enhancer, scientifically proven to support overall mental acuity, boosting focus and improving memory retention with a potent blend of DMAE, Huperzine A, Rhodiola, and Lion's Mane. Available in gummy format. Peace: Formulated to help one navigate life's occasional stresses with ease, harnessing the calming properties of Holy Basil, Lemon Balm, St. John's Wort, and L-Theanine to maximize tranquility and serenity and promote relaxation and emotional balance. Available in gummy format. ReShape: More than just a diet supplement; it's a holistic approach to promoting well-being by supporting metabolism, enhancing energy levels, and achieving weight management goals with carefully selected ingredients Berberine, OEA (oleoylethanolamide), and Cinnamon. +PlusHLTH™ adds to CV Sciences' expansive collection of health and wellness products curated to help individuals excel in their daily endeavors. Within the last year, the Company has expanded its line of +PlusCBD™ products for pets and launched a collection of +PlusCBD™ Reserve gummies.
공지 • Aug 07CV Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024CV Sciences, Inc. announced that they will report Q2, 2024 results Pre-Market on Aug 13, 2024
공지 • Jun 08CV Sciences, Inc. Elects Bill Mccorkle as DirectorsCV Sciences, Inc. at its AGM held on June 3, 2024 approved the election of Bill McCorkle as directors.
공지 • May 10CV Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024CV Sciences, Inc. announced that they will report Q1, 2024 results Pre-Market on May 14, 2024
공지 • Apr 13CV Sciences, Inc., Annual General Meeting, Jun 03, 2024CV Sciences, Inc., Annual General Meeting, Jun 03, 2024, at 10:00 Pacific Standard Time. Agenda: To elect three directors to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified, subject to prior death, resignation or removal; to ratify the selection of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; to approve, on a non-binding advisory basis, named executive officer compensation; and to consider and act upon such other business as may properly be brought before the Meeting or any adjournments or postponement thereof by or at the direction of our Board of Directors.
공지 • Mar 26CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet ChewsCV Sciences, Inc. announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBD™ Pet Hip and Joint Health Chews and +PlusCBD™ Pet Calming Care Chews. +PlusCBD™Pet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the +PlusCBD lineup are now available nationwide at select retailers and from website. The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBD™Pet has developed a premium CBD chew with the mission of providing the higher quality ingredients and best-in-class health and nutrition for cherished family members - pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, the chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in the devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, the chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions. +PlusCBD™ Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of the human consumers, including +PlusCBD™ Reserve Collection Extra Gummies, +PlusCBD™ Reserve Collection Sleep Gummies, +PlusCBD™ Daily Balance THC-Free Gummies and Softgels and +PlusCBD™ Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives.
공지 • Mar 22CV Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024CV Sciences, Inc. announced that they will report Q4, 2023 results Pre-Market on Mar 28, 2024
공지 • Dec 14CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million.CV Sciences, Inc. (OTCPK:CVSI) acquired Cultured Foods Sp. z.o.o for $0.535 million on December 7, 2023.CV Sciences, Inc. (OTCPK:CVSI) completed the acquisition of Cultured Foods Sp. z.o.o on December 7, 2023.
공지 • Nov 10CV Sciences, Inc. to Report Q3, 2023 Results on Nov 14, 2023CV Sciences, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 14, 2023
공지 • Sep 06CV Sciences, Inc. Launches Reserve Sleep GummiesCV Sciences, Inc. announced the launch of +PlusCBD™?Reserve Collection Sleep Gummies as the brand continues to expand into the sleep aid market. The +PlusCBD™? Reserve Collection product line is crafted with a proprietary blend of full-spectrum cannabinoids with rich and bold profiles, providing intense support when needed. +PlusCBD™? Reserve Sleep Gummies are the latest addition to the successful Reserve Collection, formulated for consumers that want a product specifically designed for better sleep. Reserve Sleep Gummies give consumers more out of their nightly sleep supplement with 25mg CBD, 2.5mg THC, 5mg CBN, and 3mg of melatonin per gummy. Reserve Sleep allows consumers to regulate their circadian rhythms naturally while avoiding habit-forming sleep aids. Like all +PlusCBD™? reserve products, Sleep Gummies feature a potent blend of naturally occurring CBD and THC for a broader, full-spectrum cannabinoid experience. Sleep Gummies are available in a natural blackberry flavor sweetened with organic cane sugar. In addition to Reserve Sleep Gummies, CV Sciences recently launched Daily Balance THC Free softgels in a 100mg dose. These softgels are formulated for consumers who need higher CBD concentration to achieve their wellness goals without the effects of THC. 100mg THC Free softgels are easy-to-swallow, vegan and contain a precise dose, backed by clinical research to support everyday health.
공지 • Aug 03CV Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023CV Sciences, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 14, 2023
공지 • May 10CV Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023CV Sciences, Inc. announced that they will report Q1, 2023 results at 9:30 AM, US Eastern Standard Time on May 15, 2023
공지 • Jan 19CV Sciences, Inc. Launches 30-Count of Popular +PlusCBD Reserve Collection SoftgelsCV Sciences, Inc. announced the launch of their popular +PlusCBD Reserve Collection Softgels in a 30-count bottle. This new offering will be available on +PlusCBD's' website on January 19, 2023. +PlusCBD Reserve Collection Softgels initially launched in August 2022 as the newest edition to CV Sciences' popular Reserve Collection, available in 60-count bottles. Reserve Softgels elicit feelings of relief and calm for consumers that require intense support. Featuring a 10:1 ratio of CBD to THC (12.5mg CBD to 1.25mg THC), Reserve Softgels are crafted with a full spectrum of cannabinoids to meet consumers' need states with a manageable microdose. Now offering a 30-count bottle in addition to the 60-count bottle, Reserve Softgels' size options allow consumers to better personalize their intake routines at a lower price point of $37.99 USD. The +PlusCBD Reserve Collection features a variety of product form factors, including gummies and oils in different flavors and potency. Consumers find calm, comfort and relief in the +PlusCBD Reserve Collection.
공지 • Jan 06CV Sciences, Inc. Announces Launch of ProCBD™ Product LineCV Sciences, Inc. announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively through health practitioners. Clinical strength ProCBD™ products were created with the CV Sciences Medical Advisory Board specifically to meet patient needs and to fit seamlessly with existing care plans. ProCBD™ is the only CBD supported by published investigations, randomized controlled trial, and post marketing safety review. Formulated with CV Sciences’ decarboxylated and distilled hemp extract for concentrated CBD levels that are best used under a specialist’s care, ProCBD™ is available in Roll-On, Liquids and Softgels. The ProCBD™ product line is non-GMO, gluten free, plant-based and vegan friendly.
공지 • Nov 06CV Sciences, Inc. Announces Launch of PlusCBD™ Pet Product LineCV Sciences, Inc. announced the launch of PlusCBD™ Pet, a full line of hemp extracts formulated exclusively for dogs and cats. Made with the same trusted hemp extracts used in CV Sciences’ CBD products, PlusCBD™ Pet is available in 250mg and 500mg formats with pet friendly flavors, including beef, chicken, peanut butter and salmon, as well as unflavored. PlusCBD™ Pet will be sold across the Company’s natural and online retail channels, with plans to expand into the pet specialty channel and food, drug and mass retail channel.
공지 • Oct 07CV Sciences, Inc. Announces PlusCBD™ Brand Refresh and New Product LaunchesCV Sciences, Inc. announced a comprehensive refresh of its PlusCBD™ branded product line and the launch of 30+ new PlusCBD™ products over the next 45 days. The new PlusCBD™ brand is a refinement and modernization that includes new packaging with a contemporary color palette and a post-modern aesthetic to relay each product’s value proposition across the product offering. The 30+ new product launch includes eight new, innovative products featuring extra strength gummies and maximum strength softgels. The refreshed PlusCBD™ packaging features its new, prominently displayed CV Sciences logo, transparent QR code labeling linked to lab reports to assure customers of the unrivaled quality, and the milligrams of CBD per serving on the label.
공지 • Jul 24CV Sciences, Inc. to Report Q2, 2020 Results on Aug 06, 2020CV Sciences, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020